Replies to post #171592 on Biotech Values

[ciotera]

The pill burden argument against ABBV/ENTA

Do not underestimate physicians' and patients' preference for simplicity, even when the treatment is for a set duration - why did Incivek win against Victrelis in the US market despite a significant price premium?